2-(5-PIPERIDIN-4-YL-1,2,4-OXADIAZOL-3-YL)PYRAZINE
- $78 - $466
- Product name: 2-(5-PIPERIDIN-4-YL-1,2,4-OXADIAZOL-3-YL)PYRAZINE
- CAS: 93072-94-7
- MF: C9H7NO4
- MW: 193.16
- EINECS:
- MDL Number:MFCD03426077
- Synonyms:p-Nitrophenylmalondialdehyde;5-(4-piperidinyl)-3-(2-pyrazinyl)-1,2,4-oxadiazole;Benzeneacetaldehyde, α-(hydroxymethylene)-4-nitro-
3 prices
Selected condition:
Brand
- AK Scientific
- Crysdot
- Matrix Scientific
Package
- 250mg
- 500mg
- 5g
- ManufacturerAK Scientific
- Product number3510AF
- Product description2-(5-Piperidin-4-yl-[1,2,4]-oxadiazol-3-yl)-pyrazine
- Packaging250mg
- Price$225
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11011003
- Product description5-(Piperidin-4-yl)-3-(pyrazin-2-yl)-1,2,4-oxadiazole 97%
- Packaging5g
- Price$466
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number007356
- Product description2-(5-Piperidin-4-yl-[1,2,4]-oxadiazol-3-yl)-pyrazine
- Packaging500mg
- Price$78
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | 3510AF | 2-(5-Piperidin-4-yl-[1,2,4]-oxadiazol-3-yl)-pyrazine | 250mg | $225 | 2021-12-16 | Buy |
Crysdot | CD11011003 | 5-(Piperidin-4-yl)-3-(pyrazin-2-yl)-1,2,4-oxadiazole 97% | 5g | $466 | 2021-12-16 | Buy |
Matrix Scientific | 007356 | 2-(5-Piperidin-4-yl-[1,2,4]-oxadiazol-3-yl)-pyrazine | 500mg | $78 | 2021-12-16 | Buy |
Properties
Melting point :87 °C
Boiling point :369.9±42.0 °C(Predicted)
Density :1.375±0.06 g/cm3(Predicted)
pka :3.25±0.30(Predicted)
Boiling point :369.9±42.0 °C(Predicted)
Density :1.375±0.06 g/cm3(Predicted)
pka :3.25±0.30(Predicted)
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Precautionary statements: |
|